Receptor News and Research

RSS

MEK inhibition could limit T cell exhaustion and give a boost to immunotherapy

A major pillar of cancer immunotherapy involves stimulating T cells, the specialized killers of the immune system, to attack tumors.

23 Jul 2026

AI-powered analytics and experimental validation: Transforming target identification in drug discovery

Discover how AI-powered analytics and experimental validation combine to improve target identification and accelerate drug discovery success.

From Axxam S.p.A 23 Jul 2026

Thymulin curbs age-related inflammation and slows breast tumors in mice

Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.

23 Jul 2026

GLP-1 receptor agonists may increase hair loss risk

Use of glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity are associated with an increased risk of hair loss (alopecia) in adults with type 2 diabetes, finds a study published by The BMJ today.

22 Jul 2026

Generic semaglutide could improve diabetes treatment affordability in Canada

In a novel analysis examining the economic implications of generic semaglutide entering the Canadian market, researchers predict that the anticipated price reductions of up to 70% will dramatically increase both the cost-effectiveness and health system affordability of therapy options for patients with type 2 diabetes and high cardiorenal risk.

22 Jul 2026

Newer GLP-1 medications may reduce alcohol-related hospitalization risk

Use of newer GLP-1 receptor agonists (semaglutide or tirzepatide) for obesity or diabetes by people with alcohol-use disorder was associated with a reduction in alcohol-related admissions to hospital, finds a study published online in the open access journal BMJ Open.

21 Jul 2026

AI-powered PeptiVerse could accelerate peptide drug discovery

Penn Engineers have developed PeptiVerse, an AI-powered platform that predicts key chemical and biological properties of peptides, the strings of amino acids whose medical potential has been demonstrated by the success of GLP-1 drugs, the widely used weight-loss treatments.

21 Jul 2026

Moderate coffee intake may support heart health, AHA says

The American Heart Association finds that habitual coffee consumption is associated with lower risks of several cardiovascular outcomes, although most evidence comes from observational studies. Moderate intake is generally safe for most adults, while energy drinks and individual caffeine sensitivity may increase cardiovascular concerns.

21 Jul 2026

Early electroacupuncture intervention protects pancreatic function in prediabetes

Prediabetes refers to a metabolic state in which blood glucose is higher than normal but has not yet reached the diagnostic threshold for diabetes. It may involve impaired fasting glucose, impaired glucose tolerance, or elevated glycated hemoglobin A1c (HbA1c), and is closely associated with progressive β-cell dysfunction.

21 Jul 2026

Unlocking the untapped 90%: Membrane protein purification as a three hours routine workflow

Automated, detergent-free purification preserves native membrane protein structure while supporting more reliable target validation workflows.

From Analytik Jena 21 Jul 2026

New AI score enhances monitoring of myelodysplastic neoplasms

Weill Cornell Medicine investigators have developed a new AI-based method to assess patients with a form of blood cancer called myelodysplastic neoplasms.

20 Jul 2026

Semaglutide vs. liraglutide: Head-to-head study reveals a diabetes risk difference

Researchers compared semaglutide with liraglutide in 57,456 insured adults without recorded diabetes or cardiovascular disease who initiated formulations indicated for chronic weight management. Semaglutide users had a lower risk of incident diabetes, particularly beyond six months of follow-up, but limited cardiovascular events prevented a precise comparison of cardiovascular risk.

20 Jul 2026

Semaglutide fuels rapid growth in US GLP-1RA use as payments rise

Nationally representative US data show GLP-1RA use rose 230% among adults with diabetes and 643% among those without reported diabetes between 2017 and 2022, largely driven by semaglutide. Mean annual out-of-pocket payments decreased, but mean total annual payments per user increased, raising concerns about long-term affordability.

20 Jul 2026

Gut microbial metabolites may shape vulnerability to stress-related mental disorders

Gut microbiome-derived metabolites may influence stress-related mental disorders through neural, immune, endocrine, and epigenetic pathways. Evidence is strongest for depression and preclinical models, while larger longitudinal human studies are needed to establish causality and clinical value.

20 Jul 2026

Daily polypill significantly improves cardiac function in heart failure patients

Treatment with a "polypill" that combines multiple medications into a single daily dose significantly enhanced cardiac function and reduced hospitalizations for patients with heart failure, according to a study led by Michigan Medicine and UT Southwestern Medical Center.

20 Jul 2026

GLP-1 weight-loss drugs may also reduce binge eating

Research indicates GLP-1RAs may effectively reduce binge eating severity, offering a complementary approach to existing psychological therapies for obesity.

20 Jul 2026

Popular diabetes drugs do not alter the risk of developing a blinding eye condition

An estimated 27% of U.S. adults with diabetes are using glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - a type of medication that mimics the GLP-1 hormone - to lower blood sugar and support weight loss. Some research has suggested that their use can reduce the risk of developing other diseases.

17 Jul 2026

SORLA protein may protect the brain from toxic tau tangles

Alzheimer's disease and many other forms of neurodegeneration share a common culprit. In these diseases, tau proteins that normally stabilize neuronal microtubule filaments within our nervous system networks instead form noxious knots and gradually disrupt the circuits they would otherwise preserve.

17 Jul 2026

Study detects early warning signs of schistosomiasis drug resistance

Scientists have identified genetic changes in wild populations of the parasitic worm that causes schistosomiasis which may reduce its response to praziquantel, the only available treatment.

17 Jul 2026

Immune pathway may promote the progression of oral precancerous lesions

Researchers at The University of Texas MD Anderson Cancer Center identified an immune pathway that may promote the progression of oral precancerous lesions into head and neck squamous cell carcinoma.

16 Jul 2026